Thermo Fisher Scientific Inc announced the opening of its East Coast flagship Advanced Therapies Collaboration Center (ATxCC) in Philadelphia, marking the company’s second ATxCC in the US following the opening of its Carlsbad, California, site. Together, these centres expand the company’s nationwide network supporting Cell and Gene Therapy (CGT) innovation, providing critical resources to biotech, biopharma and translational researchers developing next-generation cell-based immunotherapies.

Advanced therapies represent one of the most promising frontiers in modern medicine, offering the potential to treat, and even cure, diseases once considered untreatable. As demand for these therapies grows, so does the need for scalable and innovative solutions. The opening of Thermo Fisher’s new East Coast centre highlights the company’s ongoing investment in enabling these breakthroughs and advancing the future of healthcare.

“Our new Advanced Therapies Collaboration Center in Philadelphia is designed to help innovators overcome critical hurdles in developing Cell and Gene Therapies. This centre will play a key role in supporting customers as they progress from the lab to the clinic and, most importantly, bring transformative therapies to patients faster,” said Nicole Brockway, President, Biosciences, Thermo Fisher Scientific.

Located within BioLabs for Advanced Therapeutics Philadelphia, a newly expanded 53,000-square-foot biotech incubator in the heart of the city, the Philadelphia ATxCC provides emerging startups and biopharma organisations with direct access to Thermo Fisher’s expert scientists, advanced process development technologies and collaboration opportunities.

"We’re proud to expand our network-wide partnership with Thermo Fisher Scientific through this unique offering. By embedding the ATxCC within the BioLabs community, we are creating a uniquely rich and accessible resource for founders and startup teams working on groundbreaking therapies in Philadelphia. It will offer game-changing access to high-end technologies not only for our BioLabs members, but also to external high-potential biotechs from across the East Coast and internationally,” said Johannes Fruehauf, PhD, MD, Founder and CEO, BioLabs.